» Articles » PMID: 33452053

Modelling the Cascade of Biomarker Changes in -related Frontotemporal Dementia

Abstract

Objective: Progranulin-related frontotemporal dementia (FTD-) is a fast progressive disease. Modelling the cascade of multimodal biomarker changes aids in understanding the aetiology of this disease and enables monitoring of individual mutation carriers. In this cross-sectional study, we estimated the temporal cascade of biomarker changes for FTD-, in a data-driven way.

Methods: We included 56 presymptomatic and 35 symptomatic mutation carriers, and 35 healthy non-carriers. Selected biomarkers were neurofilament light chain (NfL), grey matter volume, white matter microstructure and cognitive domains. We used discriminative event-based modelling to infer the cascade of biomarker changes in FTD- and estimated individual disease severity through cross-validation. We derived the biomarker cascades in non-fluent variant primary progressive aphasia (nfvPPA) and behavioural variant FTD (bvFTD) to understand the differences between these phenotypes.

Results: Language functioning and NfL were the earliest abnormal biomarkers in FTD-. White matter tracts were affected before grey matter volume, and the left hemisphere degenerated before the right. Based on individual disease severities, presymptomatic carriers could be delineated from symptomatic carriers with a sensitivity of 100% and specificity of 96.1%. The estimated disease severity strongly correlated with functional severity in nfvPPA, but not in bvFTD. In addition, the biomarker cascade in bvFTD showed more uncertainty than nfvPPA.

Conclusion: Degeneration of axons and language deficits are indicated to be the earliest biomarkers in FTD-, with bvFTD being more heterogeneous in disease progression than nfvPPA. Our data-driven model could help identify presymptomatic mutation carriers at risk of conversion to the clinical stage.

Citing Articles

Characterization of Progranulin Gene Mutations in Portuguese Patients with Frontotemporal Dementia.

Almeida M, Tabuas-Pereira M, Baldeiras I, Lima M, Duraes J, Massano J Int J Mol Sci. 2024; 25(1).

PMID: 38203682 PMC: 10778719. DOI: 10.3390/ijms25010511.


Changes in Digital Speech Measures in Asymptomatic Carriers of Pathogenic Variants Associated With Frontotemporal Degeneration.

Nevler N, Cho S, Cousins K, Ash S, Olm C, Shellikeri S Neurology. 2024; 102(2):e207926.

PMID: 38165329 PMC: 11407502. DOI: 10.1212/WNL.0000000000207926.


Frontotemporal lobar degeneration.

Grossman M, Seeley W, Boxer A, Hillis A, Knopman D, Ljubenov P Nat Rev Dis Primers. 2023; 9(1):40.

PMID: 37563165 DOI: 10.1038/s41572-023-00447-0.


Clinical Value of Longitudinal Serum Neurofilament Light Chain in Prodromal Genetic Frontotemporal Dementia.

Giannini L, Seelaar H, van der Ende E, Poos J, Jiskoot L, Dopper E Neurology. 2023; 101(10):e1069-e1082.

PMID: 37491327 PMC: 10491440. DOI: 10.1212/WNL.0000000000207581.


The role of neurofilament light in genetic frontotemporal lobar degeneration.

Zetterberg H, Teunissen C, Van Swieten J, Kuhle J, Boxer A, Rohrer J Brain Commun. 2023; 5(1):fcac310.

PMID: 36694576 PMC: 9866262. DOI: 10.1093/braincomms/fcac310.


References
1.
Panman J, Jiskoot L, Bouts M, Meeter L, van der Ende E, Poos J . Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a longitudinal MRI study. Neurobiol Aging. 2019; 76:115-124. DOI: 10.1016/j.neurobiolaging.2018.12.017. View

2.
Marsel Mesulam M . Primary Progressive Aphasia and the Left Hemisphere Language Network. Dement Neurocogn Disord. 2019; 15(4):93-102. PMC: 6428021. DOI: 10.12779/dnd.2016.15.4.93. View

3.
Mann D, Snowden J . Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Brain Pathol. 2017; 27(6):723-736. PMC: 8029341. DOI: 10.1111/bpa.12486. View

4.
Grossman M . The non-fluent/agrammatic variant of primary progressive aphasia. Lancet Neurol. 2012; 11(6):545-55. PMC: 3361730. DOI: 10.1016/S1474-4422(12)70099-6. View

5.
Chitramuthu B, Bennett H, Bateman A . Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. Brain. 2017; 140(12):3081-3104. DOI: 10.1093/brain/awx198. View